Manuscripts
March 28, 2024
Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network
Learning Health Systemas
Perrey HM et al
January 10, 2024
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
Gynecologic Oncology
Szamreta EA et al
October 18, 2023
Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study
JTO Clinical & Research Reports
Behera M et al
September 20, 2023
Real-world pitfalls of analyzing real-world data: A cautionary note and path forward
JCO Clinical Cancer Informatics
Cooper JD et al
August 30, 2023
Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ Discovery analysis of the modern era [CORRESPONDENCE]
American Journal of Hematology
Gibson S et al
July 28, 2023
Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis
Clinical Lymphoma, Myeloma & Leukemia
Gibson S et al
May 23, 2023
Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices
JCO Oncology Practice
Jagsi R et al
March 26, 2023
Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ? Discovery multiple myeloma dataset
American Journal of Hematology
DeStefano CB et al
February 22, 2023
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
PharmacoEconomics - Open
Verhoek A et al
Abstracts
May 1, 2024
MP31-17: Variation in genomic testing amongst localized prostate cancer patients undergoing radical prostatectomy or radiation therapy: Results from a population-based cohort
AUA Annual Meeting 2024
Wiesen B et al
May 1, 2024
MP51-18: Population-based trends and outcomes for cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States
AUA Annual Meeting 2024
Wiesen B et al
January 29, 2024
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)
ASCO Genitourinary Cancers Symposium 2024
Bolan P et al
January 29, 2024
Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer
ASCO Genitourinary Cancers Symposium 2024
Callihan E et al
June 2, 2023
Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US)
ASCO Annual Meeting 2023
Kalinsky K et al
June 2, 2023
Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy
ASCO Annual Meeting 2023
Coutinho F et al
June 2, 2023
Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts
ASCO Annual Meeting 2023
George R et al
June 2, 2023
Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data
ASCO Annual Meeting 2023
Agrawal S et al
June 2, 2023
Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale
ASCO Annual Meeting 2023
Agrawal S et al
